These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 83086)

  • 21. Effect of vaccine prepared from Corynebacterium parvum on the growth of Gardner lymphosarcoma in C3H strain mice.
    Motycka K; Chudomel V; Bednár M; Bostík J
    Arch Immunol Ther Exp (Warsz); 1984; 32(4):405-12. PubMed ID: 6549499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
    Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coparvax for malignant effusion?
    Drug Ther Bull; 1983 Oct; 21(20):79-80. PubMed ID: 6641514
    [No Abstract]   [Full Text] [Related]  

  • 24. [Malignant hemangioendothelioma of the head in the elderly. Ultrastructural and immunohistological study].
    Kanitakis J; Bendelac A; Chouvet B; Thivolet J
    Ann Dermatol Venereol; 1985; 112(5):441-51. PubMed ID: 3898968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of immunotherapy in acute myelogenous leukemia.
    Foon KA; Smalley RV; Riggs CW; Gale RP
    Arch Intern Med; 1983 Sep; 143(9):1726-31. PubMed ID: 6577818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coagulation and fibrinolysis during the infusion of Corynebacterium parvum in man.
    Cederholm-Williams SA; King A; Allington MJ; Gill PG; Sharp AA; Britton BJ
    Br J Cancer; 1978 Jun; 37(6):1074-7. PubMed ID: 678428
    [No Abstract]   [Full Text] [Related]  

  • 27. Microscopic changes of the urinary bladder in patients with primary tumors locally treated with Corynebacterium parvum.
    Raica M; Ioart I; Gurtavenco A
    Morphol Embryol (Bucur); 1989; 35(4):275-7. PubMed ID: 2533966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The use of Corynebacterium parvum in pleurodesis].
    Helin T; Haahtela T
    Duodecim; 1988; 104(4):262-5. PubMed ID: 3168834
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapy and corynebacterium parvum for induction and maintenance of remission in acute myelogenous leukaemia--a controlled study.
    Shetty PA; Pai VR; Jani PH; Antia PK; Shahane AD
    Indian J Cancer; 1983; 20(2):119-23. PubMed ID: 6580265
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemo-immunotherapy for unresectable bronchogenic carcinoma.
    Sarna GP; Lowitz BB; Haskell CM; Dorey FJ; Cline MJ
    Cancer Treat Rep; 1978 May; 62(5):681-7. PubMed ID: 350397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
    Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
    Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant immunotherapy.
    Goodnight JE; Morton DL
    Int Adv Surg Oncol; 1978; 1():53-83. PubMed ID: 399764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the toxicity of two formulations of Corynebacterium parvum in a double-blind crossover trial in patients with bronchogenic carcinoma.
    Mitcheson HD; Priestman TJ
    Clin Oncol; 1981 Sep; 7(3):179-82. PubMed ID: 7044635
    [No Abstract]   [Full Text] [Related]  

  • 34. Combination chemoimmunotherapy for extensive non-oat cell lung cancer.
    Issell BF; Valdivieso M; Hersh EM; Richman S; Gutterman JU; Bodey GP
    Cancer Treat Rep; 1978 Jul; 62(7):1059-63. PubMed ID: 356968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Responsiveness of senescent mice to the antitumor properties of Corynebacterium parvum.
    Yuhas JM; Ullrich RL
    Cancer Res; 1976 Jan; 36(1):161-6. PubMed ID: 1247995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The complications of intravenous Corynebacterium parvum infusion.
    Gill PG; Morris PJ; Kettlewell M
    Clin Exp Immunol; 1977 Nov; 30(2):229-32. PubMed ID: 606444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of efficacy of mitomycin-C and corynebacterium parvum in the management of malignant pleural effusion.
    Yew WW; Chan SL; Kwan SY
    Chin Med J (Engl); 1988 Oct; 101(10):737-9. PubMed ID: 3150706
    [No Abstract]   [Full Text] [Related]  

  • 38. Surgery plus Corynebacterium parvum immunotherapy for Lewis lung carcinoma in mice.
    Karrer K; Rella W; Goldin A
    Eur J Cancer (1965); 1979 Jun; 15(6):867-73. PubMed ID: 499275
    [No Abstract]   [Full Text] [Related]  

  • 39. A case of malignant haemangioendothelioma treated with recombinant interleukin-2.
    Ansai S; Goto K; Aoki T; Hozumi Y; Aso K
    Clin Exp Dermatol; 1993 Sep; 18(5):470-5. PubMed ID: 8252775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.